-
公开(公告)号：EP2215268A1
公开(公告)日：2010-08-11
申请号：EP08772478.7
申请日：2008-07-09
发明人： PUGIA, Michael , MA, Rui
IPC分类号： C12Q1/68
摘要： Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM- 17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2- neu are disclosed. Compositions, dosage forms, and kits are also disclosed.
-
公开(公告)号：EP3536336A1
公开(公告)日：2019-09-11
申请号：EP18190948.2
申请日：2008-07-09
发明人： Pugia, Michael , MA, Rui
摘要： Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed.; Compositions, dosage forms, and kits are also disclosed.
-
公开(公告)号：EP2215268B1
公开(公告)日：2018-08-29
申请号：EP08772478.7
申请日：2008-07-09
发明人： PUGIA, Michael , MA, Rui
摘要： Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.
-
公开(公告)号：EP2422199B1
公开(公告)日：2018-07-25
申请号：EP10767527.4
申请日：2010-04-13
发明人： PUGIA, Michael, J. , MA, Rui
IPC分类号： G01N33/53
CPC分类号： C07K14/705 , G01N33/574 , G01N33/57415 , G01N33/6872 , G01N2333/575 , G01N2800/2821 , G01N2800/52 , G01N2800/56
摘要： Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.
-
5.发明公开MONOMERIC AND DIMERIC FORMS OF ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE 有权单体和脂联素受体片段的二聚体形式及其使用方法
公开(公告)号：EP2422199A1
公开(公告)日：2012-02-29
申请号：EP10767527.4
申请日：2010-04-13
发明人： PUGIA, Michael, J. , MA, Rui
IPC分类号： G01N33/53
CPC分类号： C07K14/705 , G01N33/574 , G01N33/57415 , G01N33/6872 , G01N2333/575 , G01N2800/2821 , G01N2800/52 , G01N2800/56
摘要： Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM- 17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.
-
-
-
-
搜索结果
5 条记录 (耗时 0.015 秒)
